?-carotene supplementation for patients with low baseline levels and decreased risks of total and prostate carcinoma

Abstract

These prespecified subgroup analyses appeared to support the idea that beta-carotene supplementation may reduce risk of prostate carcinoma among those with low baseline levels. Further follow-up of this population will help determine whether these findings are valid.